May 9 (Reuters) - Australia's competition regulator said on Thursday it will not oppose GlaxoSmithKline's GSK.L deal to buy Pfizer's PFE (NYSE:PFE).N consumer healthcare business.
The two pharmaceutical giants said in December they would combine their consumer health businesses in a joint venture that would be 68 percent-owned by the GSK.
The Australian Competition and Consumer Commission said the transaction will not substantially lesson competition.